Enfermedad de Hirschsprung, mutación del protooncogén RET y tiroidectomía profiláctica

Marcacuzco Quinto, Alberto A; Martínez Pueyo, José I; Gómez Rodríguez, Pilar; Cruz Vigo, Felipe de la.
Med. clín (Ed. impr.) ; 143(4): 185-186, ago. 2014.
Artículo en Español | IBECS (España) | ID: ibc-125687

Documentos relacionados

  1. [A Case Report of Multiple Endocrine Neoplasia Type 2A(MEN2A)Diagnosed with Medullary Thyroid Carcinoma].
  2. Selpercatinib: First approved selective RET inhibitor.
  3. Hirschsprung Disease - Clinical Relevance of RET Mutations.
  4. Medullary Thyroid Cancer - Feature Review and Update on Systemic Treatment.
  5. [Efficacy and Safety Analysis of Selpercatinib in Patients with RET Fusion-Positive Non-Small Cell Lung Cancer-Results from the Japanese Subset of a Global Phase 1/2 Study].
  6. <i>Ret</i> deficiency decreases neural crest progenitor proliferation and restricts fate potential during enteric nervous system development.
  7. RET Receptor Tyrosine Kinase: Role in Neurodegeneration, Obesity, and Cancer.
  8. Temporal trends in referrals of RET gene carriers for neck surgery to a tertiary surgical center in the era of international management guidelines.
  9. [Hereditary medullary thyroid cancer].
  10. Selpercatinib or Chemotherapy in RET Fusion-Positive NSCLC.